Ultra  	Ultra  	 FW	O
rapidly  	rapidly  	 FW	O
dissolving  	dissolving  	 FW	B-NP
repaglinide  	repaglinide  	 FW	I-NP
nanosized  	nanosized  	 FW	O
crystals  	crystals  	 NNS	O
prepared  	prepared  	 VBN	O
via  	via  	 IN	O
bottom-up  	bottom-up  	 JJ	O
and  	and  	 CC	O
top-down  	top-down  	 JJ	O
approach 	approach 	 NN	O
:  	:  	 :	O
influence  	influence  	 NN	O
of  	of  	 IN	O
food  	food  	 NN	O
on  	on  	 IN	O
pharmacokinetics  	pharmacokinetics  	 JJ	B-NP
behavior  	behavior  	 NN	I-NP
The  	The  	 DT	O
present  	present  	 JJ	O
work  	work  	 NN	O
was  	was  	 VBD	O
undertaken  	undertaken  	 VBN	O
with  	with  	 IN	O
the  	the  	 DT	O
objectives  	objectives  	 NNS	O
of  	of  	 IN	O
improving  	improving  	 VBG	O
the  	the  	 DT	O
dissolution  	dissolution  	 JJ	B-NP
velocity 	velocity 	 NN	I-NP
,  	,  	 ,	O
related  	related  	 VBN	O
oral  	oral  	 JJ	B-NP
bioavailability 	bioavailability 	 NN	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
minimizing  	minimizing  	 VBG	O
the  	the  	 DT	O
fasted 	fasted 	 NN	B-NP
/ 	/ 	 VBZ	I-NP
fed  	fed  	 VBN	I-NP
state  	state  	 NN	I-NP
variability  	variability  	 NN	I-NP
of  	of  	 IN	I-NP
repaglinide 	repaglinide 	 NN	I-NP
,  	,  	 ,	O
a  	a  	 DT	O
poorly  	poorly  	 RB	O
water-soluble  	water-soluble  	 JJ	O
anti-diabetic  	anti-diabetic  	 JJ	B-NP
active  	active  	 JJ	O
by  	by  	 IN	O
exploring  	exploring  	 VBG	O
the  	the  	 DT	O
principles  	principles  	 NNS	O
of  	of  	 IN	O
nanotechnology 	nanotechnology 	 NN	B-NP
.  	.  	 .	O
Nanocrystal  	Nanocrystal  	 JJ	B-NP
formulations  	formulations  	 NNS	I-NP
were  	were  	 VBD	O
prepared  	prepared  	 VBN	O
by  	by  	 IN	O
both  	both  	 DT	O
top-down  	top-down  	 JJ	O
and  	and  	 CC	O
bottom-up  	bottom-up  	 JJ	O
approaches 	approaches 	 NNS	O
.  	.  	 .	O
These  	These  	 DT	O
approaches  	approaches  	 NNS	O
were  	were  	 VBD	O
compared  	compared  	 VBN	O
in  	in  	 IN	O
light  	light  	 NN	O
of  	of  	 IN	O
their  	their  	 PRP$	O
ability  	ability  	 NN	B-NP
to  	to  	 TO	O
provide  	provide  	 VB	O
the  	the  	 DT	O
formulation  	formulation  	 JJ	B-NP
stability  	stability  	 NN	I-NP
in  	in  	 IN	O
terms  	terms  	 NNS	O
of  	of  	 IN	O
particle  	particle  	 JJ	B-NP
size 	size 	 NN	I-NP
.  	.  	 .	O
Soluplus®  	Soluplus®  	 NNP	B-NP
was  	was  	 VBD	O
used  	used  	 VBN	O
as  	as  	 IN	O
a  	a  	 DT	O
stabilizer  	stabilizer  	 NN	B-NP
and  	and  	 CC	O
Kolliphor™  	Kolliphor™  	 NNP	B-NP
E-TPGS  	E-TPGS  	 NNP	O
was  	was  	 VBD	O
used  	used  	 VBN	O
as  	as  	 IN	O
an  	an  	 DT	O
oral  	oral  	 JJ	B-NP
absorption  	absorption  	 JJ	I-NP
enhancer 	enhancer 	 NN	I-NP
.  	.  	 .	O
In  	In  	 IN	O
vitro  	vitro  	 JJ	B-NP
dissolution  	dissolution  	 NN	I-NP
profiles  	profiles  	 NNS	I-NP
were  	were  	 VBD	O
investigated  	investigated  	 VBN	O
in  	in  	 IN	O
distilled  	distilled  	 JJ	O
water 	water 	 NN	O
,  	,  	 ,	O
fasted  	fasted  	 NN	O
and  	and  	 CC	O
fed  	fed  	 JJ	O
state  	state  	 NN	O
simulated  	simulated  	 VBZ	O
gastric  	gastric  	 JJ	B-NP
fluid 	fluid 	 NN	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
compared  	compared  	 VBN	O
with  	with  	 IN	O
the  	the  	 DT	O
pure  	pure  	 JJ	O
repaglinide 	repaglinide 	 NN	B-NP
.  	.  	 .	O
In  	In  	 IN	O
vivo  	vivo  	 JJ	B-NP
pharmacokinetics  	pharmacokinetics  	 NN	I-NP
was  	was  	 VBD	O
performed  	performed  	 VBN	O
in  	in  	 IN	O
both  	both  	 PDT	O
the  	the  	 DT	O
fasted  	fasted  	 NN	O
and  	and  	 CC	O
fed  	fed  	 JJ	O
state  	state  	 NN	O
using  	using  	 VBG	O
Wistar  	Wistar  	 JJ	B-NP
rats 	rats 	 NNS	I-NP
.  	.  	 .	O
Oral  	Oral  	 JJ	B-NP
hypoglycemic  	hypoglycemic  	 JJ	I-NP
activity  	activity  	 NN	I-NP
was  	was  	 VBD	O
also  	also  	 RB	O
assessed  	assessed  	 VBN	O
in  	in  	 IN	O
streptozotocin-induced  	streptozotocin-induced  	 JJ	B-NP
diabetic  	diabetic  	 JJ	I-NP
rats 	rats 	 NNS	I-NP
.  	.  	 .	O
Nanocrystals  	Nanocrystals  	 NNP	B-NP
TD-A  	TD-A  	 NNP	I-NP
and  	and  	 CC	O
TD-B  	TD-B  	 NNP	B-NP
showed  	showed  	 VBD	O
19.86  	19.86  	 CD	O
and  	and  	 CC	O
25.67-fold  	25.67-fold  	 CD	O
increase  	increase  	 NN	O
in  	in  	 IN	O
saturation  	saturation  	 JJ	B-NP
solubility 	solubility 	 NN	I-NP
,  	,  	 ,	O
respectively 	respectively 	 RB	O
,  	,  	 ,	O
when  	when  	 WRB	O
compared  	compared  	 VBN	O
with  	with  	 IN	O
pure  	pure  	 JJ	O
repaglinide 	repaglinide 	 NN	B-NP
.  	.  	 .	O
Almost  	Almost  	 RB	O
10  	10  	 CD	O
( 	( 	 -LRB-	O
TD-A 	TD-A 	 NNP	B-NP
)  	)  	 -RRB-	O
and  	and  	 CC	O
15  	15  	 CD	O
( 	( 	 -LRB-	B-NP
TD-B 	TD-B 	 NNP	I-NP
) 	) 	 -RRB-	I-NP
-fold  	-fold  	 JJ	I-NP
enhancement  	enhancement  	 NN	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
oral  	oral  	 JJ	B-NP
bioavailability  	bioavailability  	 NN	I-NP
of  	of  	 IN	I-NP
nanocrystals  	nanocrystals  	 NN	I-NP
was  	was  	 VBD	O
observed  	observed  	 VBN	O
regardless  	regardless  	 RB	O
of  	of  	 IN	O
the  	the  	 DT	O
fasted 	fasted 	 NN	B-NP
/ 	/ 	 VBZ	I-NP
fed  	fed  	 VBN	I-NP
state  	state  	 NN	I-NP
compared  	compared  	 VBN	O
to  	to  	 TO	O
pure  	pure  	 JJ	O
repaglinide 	repaglinide 	 NN	B-NP
.  	.  	 .	O
Nanocrystal  	Nanocrystal  	 JJ	B-NP
formulations  	formulations  	 NNS	I-NP
also  	also  	 RB	O
demonstrated  	demonstrated  	 VBN	O
significant  	significant  	 JJ	O
( 	( 	 -LRB-	O
p    	p    	 NNP	O
< 	< 	 SYM	O
0.001 	0.001 	 NNP	O
)  	)  	 -RRB-	O
hypoglycemic  	hypoglycemic  	 JJ	B-NP
activity  	activity  	 NN	I-NP
with  	with  	 IN	O
faster  	faster  	 JJR	O
onset  	onset  	 NN	O
( 	( 	 -LRB-	O
less  	less  	 JJR	O
than  	than  	 IN	O
30  	30  	 CD	O
min 	min 	 CD	B-NP
)  	)  	 -RRB-	O
and  	and  	 CC	O
prolonged  	prolonged  	 JJ	O
duration  	duration  	 NN	O
( 	( 	 -LRB-	O
up  	up  	 RB	O
to  	to  	 TO	O
8  	8  	 CD	O
h 	h 	 CD	O
)  	)  	 -RRB-	O
compared  	compared  	 VBN	O
to  	to  	 TO	O
pure  	pure  	 JJ	O
repaglinide  	repaglinide  	 NNS	B-NP
( 	( 	 -LRB-	O
after  	after  	 IN	O
60  	60  	 CD	O
min 	min 	 NNS	B-NP
;  	;  	 :	O
up  	up  	 RB	O
to  	to  	 TO	O
4  	4  	 CD	O
h 	h 	 NN	O
,  	,  	 ,	O
respectively 	respectively 	 RB	O
) 	) 	 -RRB-	O
.  	.  	 .	O
